119 related articles for article (PubMed ID: 29385852)
1. Clinical Trial of MGMT(P140K) Gene Therapy in the Treatment of Pediatric Patients with Brain Tumors.
Kramer B; Singh R; Wischusen J; Dent R; Rush A; Middlemiss S; Ching YW; Alexander IE; McCowage G
Hum Gene Ther; 2018 Aug; 29(8):874-885. PubMed ID: 29385852
[TBL] [Abstract][Full Text] [Related]
2. In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model.
Gori JL; Beard BC; Ironside C; Karponi G; Kiem HP
Cancer Gene Ther; 2012 Aug; 19(8):523-9. PubMed ID: 22627392
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.
Adair JE; Johnston SK; Mrugala MM; Beard BC; Guyman LA; Baldock AL; Bridge CA; Hawkins-Daarud A; Gori JL; Born DE; Gonzalez-Cuyar LF; Silbergeld DL; Rockne RC; Storer BE; Rockhill JK; Swanson KR; Kiem HP
J Clin Invest; 2014 Sep; 124(9):4082-92. PubMed ID: 25105369
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow.
Kramer BA; Lemckert FA; Alexander IE; Gunning PW; McCowage GB
J Gene Med; 2006 Sep; 8(9):1071-85. PubMed ID: 16927363
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
6. F2A sequence linking MGMT(P140K) and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells.
Maier P; Heckmann D; Spier I; Laufs S; Zucknick M; Allgayer H; Fruehauf S; Zeller WJ; Wenz F
Cancer Gene Ther; 2012 Nov; 19(11):802-10. PubMed ID: 23037811
[TBL] [Abstract][Full Text] [Related]
7. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
8. Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection.
Milsom MD; Williams DA
DNA Repair (Amst); 2007 Aug; 6(8):1210-21. PubMed ID: 17482893
[TBL] [Abstract][Full Text] [Related]
9. Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.
Schambach A; Baum C
DNA Repair (Amst); 2007 Aug; 6(8):1187-96. PubMed ID: 17482894
[TBL] [Abstract][Full Text] [Related]
10. Extended survival of glioblastoma patients after chemoprotective HSC gene therapy.
Adair JE; Beard BC; Trobridge GD; Neff T; Rockhill JK; Silbergeld DL; Mrugala MM; Kiem HP
Sci Transl Med; 2012 May; 4(133):133ra57. PubMed ID: 22572881
[TBL] [Abstract][Full Text] [Related]
11. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Jiang G; Wei ZP; Pei DS; Xin Y; Liu YQ; Zheng JN
Biochem Biophys Res Commun; 2011 Mar; 406(3):311-4. PubMed ID: 21329652
[TBL] [Abstract][Full Text] [Related]
12. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells.
Ragg S; Xu-Welliver M; Bailey J; D'Souza M; Cooper R; Chandra S; Seshadri R; Pegg AE; Williams DA
Cancer Res; 2000 Sep; 60(18):5187-95. PubMed ID: 11016647
[TBL] [Abstract][Full Text] [Related]
13. In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene.
Larochelle A; Choi U; Shou Y; Naumann N; Loktionova NA; Clevenger JR; Krouse A; Metzger M; Donahue RE; Kang E; Stewart C; Persons D; Malech HL; Dunbar CE; Sorrentino BP
J Clin Invest; 2009 Jul; 119(7):1952-63. PubMed ID: 19509470
[TBL] [Abstract][Full Text] [Related]
14. Clonal inventory screens uncover monoclonality following serial transplantation of MGMT P140K-transduced stem cells and dose-intense chemotherapy.
Giordano FA; Sorg UR; Appelt JU; Lachmann N; Bleier S; Roeder I; Kleff V; Flasshove M; Zeller WJ; Allgayer H; von Kalle C; Fruehauf S; Moritz T; Laufs S
Hum Gene Ther; 2011 Jun; 22(6):697-710. PubMed ID: 21319998
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
[TBL] [Abstract][Full Text] [Related]
16. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
[TBL] [Abstract][Full Text] [Related]
17. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of MGMT(P140K) and alpha-L-iduronidase in primary hepatocytes from mucopolysaccharidosis type I mice enables efficient selection with metabolic correction.
Wang D; Worsham DN; Pan D
J Gene Med; 2008 Mar; 10(3):249-59. PubMed ID: 18076130
[TBL] [Abstract][Full Text] [Related]
19. The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine.
Woolford LB; Southgate TD; Margison GP; Milsom MD; Fairbairn LJ
J Gene Med; 2006 Jan; 8(1):29-34. PubMed ID: 16075413
[TBL] [Abstract][Full Text] [Related]
20. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
